Cancer/testis antigens (CTAs) expression in resected lung cancer.
Cancer/testis antigens (CTAs) expression in resected lung cancer.
复制标题
切除肺癌中癌症/睾丸抗原（CTA）的表达
DOI：
10.2147/ott.s159491
复制
发表时间：
2018
影响因子：
4
通讯作者：
Yu Y
中科院分区：
文献类型：
--
作者：
Jin S;Cao S;Li J;Meng Q;Wang C;Yao L;Lang Y;Cao J;Shen J;Pan B;Hu J;Yu Y
背景：越来越多的证据表明，肿瘤/睾丸抗原(CTA)在肿瘤发生中起着关键作用。前期研究发现，MAGEA1、MAGEA10、MAGEB2、KK-LC-1和CTAG1A/B在蛋白质水平上有较高的表达频率。我们的目的是在基因水平上探讨它们在肺癌切除中的预后作用及其与临床特征的相关性。方法收集38例肺癌手术标本。基于癌症基因组图谱数据库进行了验证研究。用Kaplan-Meier和多因素分析评价CTA的预后作用。结果MAGEA1(16.7%vs65.0%，P=0.004)、MAGEA10(61.1%vs95.0%，P=0.016)、MAGEB2(55.6%vs95.0%，P=0.007)和KK-LC-1(16.7%vs55.0%，P=0.020)的高表达与初诊时的淋巴结转移密切相关。Ⅱ、Ⅲ期患者MAGEA10(57.1%vs91.7%，P=0.034)和KK-LC-1(14.3%vs50.0%，P=0.039)高表达提示预后不良。亚组分析显示CTAG1a/B高表达是影响患者生存的不良预后因素(P=0.031)。虽然无统计学意义，但高表达CTAG1a/B在肺腺癌和鳞癌中也显示出相似的预后趋势。肿瘤基因组图谱数据库显示CTAG1A/B主要是由CTAG1B(NY-ESO-1，P=0.047)诱导的，CTAG1B的高表达(风险比=2.733，95%CI：1.348~5.541，P=0.005)是肺ADC的一个独立的负预后因素。结论CTA是潜在的免疫治疗候选靶点，其表达与肿瘤分期密切相关。CTAG1B高表达是肺ADC的独立阴性预后因素。
Background Increasing evidence shows cancer/testis antigens (CTAs) play a key role in oncogenesis. Our pre-study finds that MAGEA1, MAGEA10, MAGEB2, KK-LC-1, and CTAG1A/B have high expression frequencies at the protein level. We aim to explore their prognostic role and correlations with clinical characteristics in resected lung cancer at the mRNA level. Methods Thirty-eight surgical lung cancer samples were included. Validation study was performed based on The Cancer Genome Atlas database. The prognostic roles of CTAs were evaluated by Kaplan–Meier and multivariate analysis. Results High expression of MAGEA1 (16.7% vs 65.0%, P=0.004), MAGEA10 (61.1% vs 95.0%, P=0.016), MAGEB2 (55.6% vs 95.0%, P=0.007), and KK-LC-1 (16.7% vs 55.0%, P=0.020) was closely correlated with lymph node metastasis at diagnosis. Patients with TNM stage II or III had a higher expression of MAGEA10 (57.1% vs 91.7%, P=0.034) and KK-LC-1 (14.3% vs 50.0%, P=0.039) compared with patients in TNM stage I. High CTAG1A/B expression showed unfavorable prognosis in all cases (P<0.05). Subgroup analysis showed high CTAG1A/B expression was a negative prognostic factor of survival (P=0.031) in patients with TNM stage II or III. Although no statistical significance was reached, high CTAG1A/B also showed a similar prognostic trend in lung adenocarcinoma (ADC) and squamous cell carcinoma. The Cancer Genome Atlas database showed the negative prognostic role of CTAG1A/B was mainly induced by CTAG1B (NY-ESO-1, P=0.047) and high CTAG1B expression (hazard ratio =2.733, 95% CI: 1.348–5.541, P=0.005) was an independent negative prognostic factor of lung ADC. Conclusion CTAs represent potential candidate targets for immunotherapy and their expression was closely correlated with tumor stage. High CTAG1B expression was an independent negative prognostic factor of lung ADC.